K-numberK241266
Device nameImaging system of positron emission and X-ray computed tomography (DigitMI 930)
ApplicantRaysolution Healthcare Co., Ltd.
Product codeKPS
Device classClass II
Decision dateJan 27, 2025
DecisionSubstantially Equivalent
Regulation892.1200
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The DigitMI 930 is a PET/CT imaging system that combines positron emission tomography with X-ray computed tomography to produce attenuation-corrected PET images. It is intended for qualified healthcare professionals to image the distribution of positron-emitting radiopharmaceuticals for metabolic and physiologic assessment across various organ systems and disease states, including oncology, cardiology, and neurology applications. The system can also function as a standalone diagnostic CT imaging device.

Technological characteristics

The proposed device features a 72-ring LYSO detector for the PET component and 64 physical rows of detectors for the CT component, with continuous rotation and multiple scan modes (topo axial and helical). Performance specifications show differences from the predicate in sensitivity, NECR peak value, peak true count rate, scatter fraction, count rate bias, spatial resolution (FWHM), scan speed, and maximum table load, though the proposed device has been tested to verify measurement accuracy and effectiveness through performance testing and software validation.

Test standards cited

The device was tested against IEC 60601-1:2020, IEC 60601-1-3:2021, IEC 60601-1-2:2020, ISO 10993-5:2009, ISO 10993-10:2021, ISO 10993-23:2021, NEMA NU 2:2018, NEMA XR 25:2019, NEMA XR 28:2018, IEC 60601-2-28:2017, IEC 60601-2-44:2016, IEC 61223-2-6:2006, IEC 61223-3-5:2019, NEMA PS3.1-3.20:2022d, and ISO 60825-1:2014.

Substantial equivalence argument

The proposed device meets the same regulatory classification (Class II), uses identical product codes (KPS, JAK), and is governed by the same regulations (21 CFR 892.1200 and 892.1750) as the predicate Discovery MI. Although performance specifications differ, these differences are characterized as slight variations that do not substantially influence effectiveness and safety, as demonstrated by the device's compliance with applicable safety and performance standards. The basic design principle, usage, and intended indications are the same between the proposed device and predicate, with differences attributable to refinements in detector technology and measurement capabilities rather than fundamental changes in intended function.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →